There are 3161 resources available
762P - First results from phase II dose expansion cohort of transcon IL-2 β/γ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial
Presenter: Oladapo Yeku
Session: Poster session 02
763P - Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Presenter: Pamela Soberanis Pina
Session: Poster session 02
765P - HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers
Presenter: Dahye Lee
Session: Poster session 02
766P - A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC)
Presenter: Jianqing Zhu
Session: Poster session 02
767P - Ovarian cancer risk factors in relation to family history
Presenter: Guoqiao Zheng
Session: Poster session 02
768P - Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status
Presenter: Etienne Rouleau
Session: Poster session 02
770P - Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
Presenter: Lot Aronson
Session: Poster session 02
771P - Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Presenter: Daisuke Shintani
Session: Poster session 02
772P - Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Presenter: Jalid Sehouli
Session: Poster session 02